论文部分内容阅读
针对我国常见急淋白血病,我们制备了CD10、CD7、CD9类依赖补体细胞毒性抗体55,LN67-8, LS93-2及DS21。系统地观察了它们固定补体的细胞毒作用后,系用活细胞沤染及集落培养技术,研究了上述抗体对骨髓中相应靶细胞最佳净化条件,特异性清除效率,联合使用有关抗体对异质性靶细胞清除效果,以及净化处理对造血祖细胞影响。为过渡临床,对大量骨髓细胞的分离、浓缩、净化及非冰冻短期保存效果也进行了探讨,摸索出一套适合我国国情的急淋白血病患者大量骨髓净化的可行方案。在此基础上,对5例普通型急淋患者缓解期自体骨髓进行净化处理,再行移植。临床结果表明,患者在强化放化疗后辅以净化自体骨髓移植,2～4周造血重建,3～8周患者离开层流室。除1例48岁女患者于移植后8个月因白血病复发死亡外,其余4例到目前为止仍处于无病活存状态。1例22岁女性患者无病活存己达20个月。初步临床效果表明,这组依赖补体的细胞毒性抗体可用于急淋患者自体骨髓净化,为临床研究净化自体骨髓提供了有力手段
For the common acute lymphoblastic leukemia in our country, we prepared CD10, CD7, CD9 dependent complement cytotoxic antibody 55, LN67-8, LS93-2 and DS21. After systematically observing the cytotoxity of their fixed complement, this study investigated the optimal purification conditions, specific removal efficiencies and specific antibody-related effects of the above antibodies on corresponding target cells in bone marrow using live cell staining and colony culture techniques Qualitative target cell clearance, and the effect of decontamination on hematopoietic progenitor cells. For the transitional clinical, a large number of bone marrow cells separation, concentration, purification and non-freezing short-term preservation effect were also explored to explore a set of suitable for China’s national conditions of patients with acute leukemia a lot of bone marrow purification feasible scheme. On this basis, five cases of common type acute lymphoblastic remission autologous bone marrow purification treatment, and then transplanted. Clinical results show that patients with enhanced autologous radiotherapy and chemotherapy combined with autologous bone marrow transplantation, 2 to 4 weeks of hematopoietic reconstitution, 3 to 8 weeks patients leave the laminar flow room. Except for a 48-year-old woman who died of leukemia at 8 months after transplantation, the remaining 4 patients were still alive in the disease so far. A 22-year-old female patient survived without disease for 20 months. Preliminary clinical results show that this group of complement-dependent cytotoxic antibodies can be used for the purification of autologous bone marrow in patients with acute lymphoblastic leukemia, providing a powerful tool for clinical research to purify autologous bone marrow